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AbstrAct
This prospective service evaluation aimed to 
determine if integrated psychological support for 
patients with inflammatory bowel disease (IBD) 
enhanced outcomes. 75 patients were assessed 
and treated by a specialist liaison psychiatric 
service between 2015 and 2017; 43 received 
psychiatric intervention alone, 32 were referred 
for psychological intervention by clinical health 
psychologist; 26 completed this. Pre–post data 
(n=15 available) included global impression, quality 
of life, and psychiatric and IBD symptom scores. 
Referrer/patient satisfaction and cost- effectiveness 
were retrospectively calculated. Psychological 
intervention led to reductions in IBD symptoms 
(ΔSIBD; p=0.003), alongside improvements 
in depression scores (ΔPHQ-9, p=0.006) and 
global impression (ΔCGI; p=0.046). Patient/
referrer satisfaction was very high. Indicative data 
comparing service utilisation 1 year before and 
after engagement found reductions in outpatient 
appointments and in imaging. This small study 
suggests consideration of increased access to 
integrated psychological support services to 
improve outcomes and gather further evidence of 
efficacy.
IntroductIon
Inflammatory bowel disease (IBD) is a life-
long condition. Estimated annual incidence 
in Europe is 24.3 and 12.7 per 100 000 
person- years for ulcerative colitis and 
Crohn’s disease, respectively. It can occur 
at any age, but is more common in younger 
people. Education, work, social and family 
life can all be disrupted by the unpredict-
able nature of debilitating and embarrassing 
symptoms. There is no ‘complete’ cure for 
IBD and many patients are on medications 
with unpleasant side effects, yet despite this 
end up needing invasive surgery with consid-
erable impact on quality of life. Comorbid 
mood disorder can affect quality of life in 
patients with IBD.1 Unsurprisingly, patients 
with IBD are twice as likely to suffer from 
depression and are also more likely to have 
an anxiety disorder than other people.2 
IBD standards have previously stated that 
a psychologist or counsellor is among the 
‘essential supporting services’ that the 
IBD team should have access to.3 Further-
more, this has been identified locally at a 
trust level by the IBD Patient Panel as an 
area of priority need. Despite this, growing 
evidence suggests that psychological stress 
can increase activity of IBD.4 However, 
there is insufficient access to psychological 
support services for patients with IBD in the 
UK. Current evidence demonstrates that 
psychological therapies improve quality 
of life in the short term and supports the 
efficacy of antidepressant medication in 
improving disease activity.
The aim of this pilot service (named 
Psychological Support Service for Patients 
with Inflammatory Bowel Disease 
(PSSPIBD)) was to introduce integrated 
multidisciplinary psychiatric and psycho-
logical support for patients with IBD. It was 
hoped that by providing high- quality mental 
health support, we would improve patients’ 
psychological wellbeing, how they interact 
with services (by reducing inappropriate 
service use) and their quality of life. This 
service evaluation assessed the key assump-
tion that providing tailored psychological 
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Figure 1 Reasons for referral into the service (1A), patient flow diagram (1B). PSSPIBD, Psychological Support Service for Patients with 
Inflammatory Bowel Disease.
support to patients with IBD will result in improved 
outcome measures across a ‘balanced scorecard’ of four 
dimensions: clinical effectiveness, cost- effectiveness, 
patient satisfaction and referrer satisfaction. Thus, it was 
our aim to demonstrate
1. Clinical effectiveness prospectively using validated ques-
tionnaires pre–post specialist psychological intervention
2. Cost- effectiveness retrospectively by indicatively evalu-
ating service use prior to and after engagement with the 
service (PSSPIBD)
3. Patient satisfaction by the use of qualitative feedback.
4. Referrer satisfaction by the use of qualitative feedback.
Methods And pArtIcIpAnts
A digestive disease centre at a teaching hospital 
secured funding to pilot a PSSPIBD, to provide outpa-
tient psychiatric and psychological support to patients 
with IBD. Between October 2015 and March 2017, 75 
patients were assessed and treated by PSSPIBD, staffed 
by a liaison psychiatrist (0.1WTE) and a band 7 clin-
ical health psychologist (0.3WTE) with special inter-
ests in IBD, enhanced by a shadowing period spent 
within the centre. Referrals were made for patients 
experiencing psychological difficulties related to their 
IBD by medical staff IBD nurses, pharmacists and 
stoma nurses; either by letter or discussion with the 
liaison psychiatrist in the weekly IBD multidisciplinary 
meeting. The service was open to all patients with IBD 
using the centre for management of IBD.
All patients referred were seen for an initial assess-
ment unless they were already under the care of 
secondary mental health services.
The most common reason for referral into the service 
was support adjusting to IBD and its symptoms (eg, 
pain, fatigue, incontinence, tolerating uncertainty) 
(39%), followed by anxiety (31%) and low mood (8%) 
(figure 1A). Seventy- one per cent of patients seen were 
women.
A subgroup (n=15) of the service had complete 
questionnaire measurements before and after receiving 
psychological intervention by a clinical health psychol-
ogist. Cognitive- behavioural therapy (CBT) was 
offered to support a range of difficulties, including 
lifting low mood, tolerating uncertainty, overcoming 
phobias and pain management. On average, patients 
received five sessions of CBT, although in practice this 
ranges from 1 session to 11 sessions. Validated ques-
tionnaires collected prospectively measured quality of 
life (EUROQoL), depression (Patient Health Question-
naire, PHQ-9), anxiety (GAD-7) and IBD symptoms 
(SIBD). In addition, clinicians rated patients globally 
(Clinical Global Impression, CGI).
Given the small numbers, analysis of effectiveness of 
intervention of therapy (clinical and cost) was conducted 
by a related samples Wilcoxon signed- rank test in SPSS 
V.25 for Mac. Change in outcome scales were correlated 
using Spearman correlation. Cost- effectiveness was deter-
mined by indicative data comparing service use in 1 year 
before and after engaging with the PSSPIBD from one 
clinician using the service (MAS). This explored inpatient 
stays, emergency department attendance, radiological 
imaging, endoscopy and outpatient appointments pre–
post. For statistical tests, a significance level of p≤0.05 
was used. Patient and referrer feedback were assessed by 
invited questionnaire to all patients and referrers.
results
Figure 1B explains the flow of patients assessed and 
treated by the service.
clinical effectiveness
Short IBD Questionnaire (SIBD) scores pre- 
psychological and post- psychological therapy showed 
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Figure 2 Clinical effectiveness: statistically significant changes 
in patient outcomes post therapy: 1A mean SIBD (IBD symptoms) 
score (±1 SEM), 1B mean PHQ-9 (depression) score (±1 SEM) and 1C 
mean clinical global improvement (±1 SEM). Positive correlations 1D 
between improvement in quality of life and improvement in bowel 
symptoms and positive correlation 1E between reduction in anxiety 
and improvement in quality of life.
Figure 3 Patient (A) and referrer (B) satisfaction with the service.
significant reductions in symptoms across all domains 
(p=0.003) with notable trend to improvement in 
bowel (p=0.067) and systemic symptoms (p=0.085) 
and significant improvements in emotional (p=0.004) 
and social functioning (p=0.046). Statistically signif-
icant improvements were seen in PHQ-9 depres-
sion score (p=0.006) and CGI (p=0.046), and there 
was a trend towards improvement in quality of life 
(EuroQoL) (p=0.058) (figure 2A–E).
Reduction in anxiety correlated with improvement 
in quality of life (r, 0.728 p=0.005) (figure 2E). There 
was a trend towards improvement in quality of life 
correlating with change in IBD symptoms (r, 0.502, 
p=0.056) (figure 2D).
service utilisation
Indicative data comparing service use in 1 year before 
and after engaging with PSSPIBD found a statistically 
significantly reduction in outpatient appointments by 
62.5% (p=0.010) and a strong trend in reduction of 
CT and MRI scans by 76.2% (p=0.058). No signif-
icant differences were found for inpatient bed days, 
emergency visits or endoscopy visits.
patient and referrer satisfaction
Patient and referrer satisfaction with the service were 
very high: 90% of patients and all referrers completing 
the feedback rated the service as excellent (figure 3A,B).
dIscussIon
The pilot service demonstrated significant improve-
ments across all symptoms domains in patients with 
IBD, notably IBD and psychiatric symptomatology. 
This improvement is arguably comparable with that 
found with use of biologic agents.5 We demonstrated 
potential cost- effectiveness and high patient and 
referrer satisfaction.
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Our findings are in keeping with the literature that 
demonstrates a high degree of psychiatric and psycho-
logical morbidity in patients with IBD. Sadly, only a 
low proportion of patients with IBD have access to 
specialist psychiatric consultation and psycholog-
ical therapy, with reasons being stigma of receiving a 
mental health service, lack of expertise and training 
in psychological assessment for many practitioners, 
and commissioning structures separating physical and 
mental health outcomes. To date, only three long- 
term conditions have an established evidence base of 
psychological need and care and psychological service 
innovations to meet such need: diabetes, chronic 
obstructive pulmonary disease and coronary heart 
disease. It is anticipated as the evidence for psycholog-
ical need and psychological effectiveness with patients 
with IBD grows, so too will the financial investment.  
limitations
The major limitation to this study is the small numbers 
and missing data. This is a problem with conducting 
rigorous service evaluation in a busy unit without dedi-
cated research infrastructure support. There is a possi-
bility of referral bias.
In terms of bias, those patients with the most regular 
contact with the IBD team were perhaps more likely 
to be referred. This group will contain those who had 
more active IBD, but also those with health- related 
anxiety and potentially medically unexplained symp-
toms. We do not feel that this in any way invalidates 
the results as these are exactly the patients that we 
wanted to reach with this service and which other 
units would want to see results for.
We believe there should be increased access to 
specialist integrated psychological support services 
across gastroenterology with the aim of gathering 
further evidence of success across all domains.
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